![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Lower Dose of Adapt Pharma’s Overdose Therapy Narcan
FDA Approves Lower Dose of Adapt Pharma’s Overdose Therapy Narcan
February 6, 2017
The FDA approved a 2-mg formulation of Adapt Pharma’s nasal spray Narcan to treat a known or suspected opioid overdose.
The dose is indicated for opioid-dependent patients expected to be at risk for severe opioid withdrawal, the company said.
In November 2015, Adapt received approval for a 4-mg formulation of Narcan as the first nasal spray version of naloxone hydrochloride.
Upcoming Events
-
21Oct